RSS Feeds
Search

Press releases

Press releases

Displaying 1..10 of 294 - per page Next page
Order by
Simple online tool avoids counter-productive rejecting of meeting requests; doubtful requests are verified or withdrawn by requesting party. More
Two papers on Embil's novel triple-active topical products (Neo-Penotran® Forte and Neo-Penotran® Forte-L) have been accepted for presentation at the 4'th World Conference on Vaginitis, Costa Rica, 10-13 Jan 2004 More
Genesis 2010, Westminster, Thursday 9 December is on track to attract a larger than ever attendance to debate new medicines and healthcare products research. More
The International Journal of Clinical Pharmacology and Therapeutics April 2009 Issue has published the latest peer-reviewed science on TDS-Testosterone. More
Labtec GmbH, Langenfeld, Germany announces the start of the phase II clinical development program for its sufentanil transdermal patch. More
FDA ISSUED ORDERS TO SOLVAY AND AUXILIUM TO ADD BLACK BOX LABELS TO THEIR PRODUCTS AS NOTIFICATION TO USERS OF DANGER OF UNINTENDED TRANSFERENCE OF TESTOSTERONE TO FAMILY MEMBERS. TRANSDERMAL TECHNOLOGIES TDS-TESTOSTERONE'S RAPIDLY ABSORBED FORMULA WILL More
An HIV/AIDS vaccine developed by University of Western Ontario professor Chil-Yong Kang has reached "an important milestone" as it pushes towards the first phase of human trials. More
Unique Low T treatment expected to eliminate the problematic transference side effect More
Postec (TM) is more efficacious than isolated topical steroid in the non surgical treatment of phimosis in children and adults More
London UK, 11 April 2012 - Based on its recent analysis of the responsive polymer for bio-medical application market, Frost & Sullivan recognises CIS Pharma with the 2011 European Frost & Sullivan Technology Innovation Award for its unique Cellophil™ bio- More
Displaying 1..10 of 294 - per page Next page
Order by

Related Reports

Clients in focus...

Get the Flash Player to see this rotator.

© Copyright 1998-2014 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us